Byron C Hann
Overview
Explore the profile of Byron C Hann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang H, Muir R, Gonciarz R, Olshen A, Yeh I, Hann B, et al.
J Exp Med
. 2022 Mar;
219(4).
PMID: 35262628
KRAS mutations drive a quarter of cancer mortality, and most are undruggable. Several inhibitors of the MAPK pathway are FDA approved but poorly tolerated at the doses needed to adequately...
2.
Dodagatta-Marri E, Ma H, Liang B, Li J, Meyer D, Chen S, et al.
Cell Rep
. 2021 Jul;
36(1):109309.
PMID: 34233193
αvβ8 integrin, a key activator of transforming growth factor β (TGF-β), inhibits anti-tumor immunity. We show that a potent blocking monoclonal antibody against αvβ8 (ADWA-11) causes growth suppression or complete...
3.
Nix M, Mandal K, Geng H, Paranjape N, Lin Y, Rivera J, et al.
Cancer Discov
. 2021 Mar;
11(8):2032-2049.
PMID: 33727310
Alternative strategies are needed for patients with B-cell malignancy relapsing after CD19-targeted immunotherapy. Here, cell surface proteomics revealed CD72 as an optimal target for poor-prognosis /-rearranged (MLLr) B-cell acute lymphoblastic...
4.
Sherbenou D, Su Y, Behrens C, Aftab B, Perez de Acha O, Murnane M, et al.
Clin Cancer Res
. 2020 Sep;
26(22):6028-6038.
PMID: 32917735
Purpose: New therapies have changed the outlook for patients with multiple myeloma, but novel agents are needed for patients who are refractory or relapsed on currently approved drug classes. Novel...
5.
Harel E, Drake P, Barfield R, Lui I, Farr-Jones S, Veer L, et al.
Antibodies (Basel)
. 2019 Nov;
8(4).
PMID: 31694242
A promising molecular target for aggressive cancers is the urokinase receptor (uPAR). A fully human, recombinant antibody that binds uPAR to form a stable complex that blocks uPA-uPAR interactions (2G10)...
6.
Su Y, Liu Y, Behrens C, Bidlingmaier S, Lee N, Aggarwal R, et al.
JCI Insight
. 2018 Sep;
3(17).
PMID: 30185663
Although initially responsive to androgen signaling inhibitors (ASIs), metastatic castration-resistant prostate cancer (mCRPC) inevitably develops and is incurable. In addition to adenocarcinoma (adeno), neuroendocrine prostate cancer (NEPC) emerges to confer...
7.
Lam C, Ferguson I, Mariano M, Lin Y, Murnane M, Liu H, et al.
Haematologica
. 2018 Apr;
103(7):1218-1228.
PMID: 29622655
The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Activation of JAK/STAT signaling is thought to be a central component of these microenvironment-induced phenotypes....
8.
Sherbenou D, Aftab B, Su Y, Behrens C, Wiita A, Logan A, et al.
J Clin Invest
. 2016 Nov;
126(12):4640-4653.
PMID: 27841764
Multiple myeloma is incurable by standard approaches because of inevitable relapse and development of treatment resistance in all patients. In our prior work, we identified a panel of macropinocytosing human...
9.
LeBeau A, Lee M, Murphy S, Hann B, Warren R, Delos Santos R, et al.
Proc Natl Acad Sci U S A
. 2012 Dec;
110(1):93-8.
PMID: 23248318
Proteases responsible for the increased peritumoral proteolysis associated with cancer represent functional biomarkers for monitoring tumorigenesis. One attractive extracellular biomarker is the transmembrane serine protease matriptase. Found on the surface...
10.
Darragh M, Schneider E, Lou J, Phojanakong P, Farady C, Marks J, et al.
Cancer Res
. 2010 Feb;
70(4):1505-12.
PMID: 20145119
The cell surface protease membrane-type serine protease-1 (MT-SP1), also known as matriptase, is often upregulated in epithelial cancers. We hypothesized that dysregulation of MT-SP1 with regard to its cognate inhibitor...